Search NLS News

The pharma giant has completed the acquisition of TeneoTwo (announced July 5 2022), including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluation in relapsed and refractory B-cell non-Hodgkin lymphoma. AstraZeneca will develop TNB-486 as a potential new medicine for B-cell haematologic malignancies. An upfront payment of 100 million USD AstraZeneca has acquired […]

Idogen has announces that Anders Karlsson has decided to leave the company to move on to a CEO role in another Swedish biotechnology company. “It has been a privilege to lead Idogen for the past three years and I am convinced that the company’s competent board and employees will continue to deliver significant progress for […]

Elypta has announced the appointment of Volker Liebenberg as Chief Medical Officer. “We are truly delighted to have Dr. Liebenberg join the team. He brings a wealth of experience in IVD development to Elypta and shares our belief in the potential for liquid biopsies to drive early detection of cancer,” says Karl Bergman, Elypta CEO. […]

AstraZeneca and Daiichi Sankyo’s Enhertu has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy. Enhertu is a specifically […]

Orion’s collaboration partner Bayer has announced the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The approval is based on positive results of the Phase III […]

Zealand Pharma has given formal notice to Nasdaq of the company’s intention to voluntarily remove its American Depositary Shares (ADSs) from listing on the New York-based Nasdaq Global Select Market. One ADS currently represents one ordinary share in Zealand Pharma, and today the company’s ADSs account for less than 1.5% of the total share capital. […]

Turning down the thermostat seems to make it harder for cancer cells to grow, according to a study in mice by researchers at Karolinska Institutet. The study, published in the journal Nature, found that chilly temperatures activate heat-producing brown fat that consumes the sugars the tumors need to thrive. Similar metabolic mechanisms were found in […]

The development-stage pharmaceutical company Transpire Bio has announced a definitive agreement with Recipharm to develop TRB-1 and TRB-2, inhaled medicines for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). TRB-1 and TRB-2, the first products developed by Transpire Bio will be indicated for the treatment of asthma and COPD, intended for advanced markets. […]

Ultomiris (ravulizumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. If authorised, Ultomiris would be the first and only approved long-acting C5 complement inhibitor for the treatment of AChR antibody-positive gMG in […]

BioInvent International has announced treatment of the first patient in a Phase 1/2a trial of its second anti-FcyRIIB antibody BI-1607 in combination with trastuzumab in HER2+ solid tumors. The first-in-human Phase 1 trial is a dose escalation study of BI-1607 combined with trastuzumab in HER2+ advanced or metastatic solid tumors. The selected dose of BI-1607 […]